Fresenius Medical Care AG & Co. KGaA (FMS) is well-poised for growth on the back of a broad range of dialysis products and services and a solid global foothold. However, stiff competition remains a concern.Shares of this Zacks Rank #3 (Hold) company have lost 7.7% year to date against the industry’s growth of 7%. The S&P 500 Index has increased 9.2% in the same time frame.The company, with a market capitalization of $11.09 billion, is one of the largest integrated providers of products and services for indi ...

Fresenius Medical Care AG & Co. KGaA (FMS) reported fourth-quarter 2023 adjusted earnings per share (EPS) of 47 cents, which beat the Zacks Consensus Estimate of 36 cents by 30.6%. The bottom line improved 6.8% year over year.Revenue DetailsRevenues of $5.37 billion (EUR 4,988 million) beat the Zacks Consensus Estimate by 0.9%. The company’s reported revenues were flat year over year but recorded a growth of 7% at constant currency (cc) and 3% on an organic basis.Segmental DetailsFresenius Medical implement ...

Fresenius Medical Care AG (NYSE:FMS) Q4 2023 Earnings Conference Call February 20, 2024 8:00 AM ET Company Participants Dominik Heger - Head of Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Victoria Lambert - Berenberg Richard Felton - Goldman Sachs Hassan Al-Wakeel - Barclays Hugo Solvet - BNP Operator At this time, it's my pleasure to hand over to Dominik Heger, Head of Investor Relations. Please go ahead, sir. Thank ...

▪ Solid organic revenue growth driven by both operating segments 4 2023 – Payors favor home treatments Investor Relations │ Analyst Presentation Q4 2023 Page 11 Low priority on M&A activities 2 Q4 Business Update Outlook Q4 2023 | Key developments at Group level ▪ Broadly stable U.S. same market treatment growth ▪ Operating income (outlook base) increased due to strong FME25 savings, the Tricare settlement and pricing in Care Enablement ▪ Realization of FME25 savings continued ahead of plan ▪ Value-based ca ...

Exhibit 99.1 Press Release Media contact Christine Peters T +49 160 6066 770 christine.peters@freseniusmedicalcare.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@freseniusmedicalcare.com www.freseniusmedicalcare.com February 20, 2024 Fresenius Medical Care delivers on commitments in a year of fundamental transformation Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "In 2023, we delivered on our commitments while we fundamentally transformed F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number 001-32749 FRESENIUS MEDICAL CARE AG (Exact name of Registrant as specified in its charter) FR ...

Fresenius Medical Care (FMS) recently announced the receipt of FDA 510(k) clearance for the company’s 5008X Hemodialysis System.The new system is aimed at providing an improved standard of care in dialysis therapy to patients suffering from kidney diseases in the United States. The FDA clearance will allow the company to start clinical evaluations and user studies in the United States.Price PerformanceFor the past six months, FMS’s shares have declined 24.0% against the industry’s growth of 6.0%. The S&P 50 ...

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q3 2023 Earnings Conference Call November 2, 2023 10:30 AM ET Company Participants Helen Giza - CEO Martin Fischer - CFO Veronika Dubajova - Citigroup Richard Felton - Goldman Sachs Group Operator As already mentioned, we would like to welcome you to our earnings call for the third quarter 2023. We appreciate you joining us today to discuss the performance of the third quarter. I'm aware that there is, with GLP-1, one dominant topic in health care research ove ...

Hi, hello. Thanks a lot to taking my question. I have one on FME25. You're at about like €60 million, €61 million benefit in Q2, you were at about the same level in Q1. So just wondering as we think about timing and phasing for Q3 and Q4 to reach that €250 million, €300 million by year-end? That would be my first question. And second on China, I remember you said it was an anomaly of strong growth in Q1. Just wondering what you saw in the Q2. Thank you. Thank you, everybody. Have a good summer. Take care. I ...

Exhibit 99.1 Filed by Fresenius Medical Care AG & Co. KGaA (Commission File No. 001-32749), pursuant to Rules 165 and 425 under the Securities Act of 1933, as amended This Exhibit consists of a convenience English translation of Fresenius Medical Care AG & Co. KGaA's (FME) Conversion Report issued in connection with its a proposed conversion of the legal form of FME. Under the U.S. Securities Act of 1933, as amended (the Securities Act), this Exhibit may be deemed to be offering material of FME. FME has fil ...